Lycopene Phytosterol Synergistic Composition Prostate Cell Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing carotenoids like lycopene lack effective inhibition of nitric oxide production and tumor necrosis factor-alpha, which are key inflammatory mediators, and have suboptimal ratios of lycopene to phytosterols, limiting their therapeutic efficacy in conditions such as prostate cancer and inflammatory disorders.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of tomato oleoresin with specific ratios of lycopene to phytosterols (between 0.9:1 and 4.7:1), including beta-sitosterol, Campesterol, and Stigmasterol, along with other carotenoids and fatty acids, to achieve synergistic inhibition of prostate cell growth and inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmaceutical compositions contain carotenoids like lycopene, then antioxidant properties and beneficial health effects are provided, but effective inhibition of nitric oxide production and tumor necrosis factor-alpha is lacking
Solution Approach 1:
The patent combines lycopene with phytosterols (beta-sitosterol, Campesterol, Stigmasterol) in specific ratios to create a synergistic composition. This merging of compounds addresses the limitation of lycopene alone by adding phytosterols that provide the missing inhibition of nitric oxide and TNF-alpha production, while lycopene provides antioxidant properties.
Solution Approach 2:
The patent specifies precise ratio parameters for lycopene to phytosterols (between 0.9:1 and 4.7:1) to optimize therapeutic efficacy. By controlling these compositional parameters, the composition achieves both antioxidant effects from lycopene and anti-inflammatory effects from phytosterols, resolving the contradiction between providing health benefits and inhibiting harmful mediators.
2Reliability
If compositions use suboptimal ratios of lycopene to phytosterols, then manufacturing is simplified, but therapeutic efficacy in prostate cancer and inflammatory disorders is limited
Solution Approach 1:
The patent establishes specific ratio parameters (lycopene to phytosterols between 0.9:1 and 4.7:1) that define the optimal formulation range. Within this parameter range, the composition achieves synergistic therapeutic effects while allowing flexibility in exact formulations, thus balancing efficacy with manufacturing feasibility.
Solution Approach 2:
The patent creates a composite pharmaceutical composition with a defined structure containing lycopene and phytosterols in specific ratios. This composite approach ensures therapeutic efficacy through synergistic interactions while the defined ratio range provides manufacturing flexibility, resolving the contradiction between complexity and effectiveness.
3Reliability
If compositions include multiple phytosterols (beta-sitosterol, Campesterol, Stigmasterol), then synergistic inhibition of prostate cell growth is achieved, but composition complexity increases
Solution Approach 1:
The patent merges three specific phytosterols (beta-sitosterol, Campesterol, and Stigmasterol) with lycopene to achieve synergistic inhibition of prostate cell growth. This combination leverages the complementary activities of different phytosterols, where each contributes to the overall anti-proliferative effect, justifying the increased compositional complexity through enhanced therapeutic reliability.
Solution Approach 2:
The patent formulates a composite material containing multiple phytosterols in specific proportions alongside lycopene. This composite structure enables synergistic inhibition of prostate cell growth that none of the individual components could achieve alone, while the defined formulation provides a systematic approach that manages complexity through standardized composition.
Data Source
Figure 1A~1C
Figure 1D~1E
Figure 2
AI summary
Pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a synergistic combination of a carotene and at least one phytosterol wherein the ratio of said lycopene to said phytosterol in said pharmaceutical composition is a maximum of about 5:1 and wherein said composition produces a synergistic inhibition of cell growth and anti-inflammatory effects are disclosed.